Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired

NCT01342952 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01342952
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01342952 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long Term Extension Study for Treatment of Pulmonary Arterial Hypertension in Paediatric Patients Aged 8 Years up to 18 Years Who Have Participated in AMB112529 and in Whom Continued Treatment With Ambrisentan is Desired
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
June 21, 2011
Completion date
June 9, 2022
Enrollment
38 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension, pulmonary